NasdaqGM:XENE
NasdaqGM:XENEBiotechs

Is Analyst Excitement Over Xenon's (XENE) Neuroscience Pipeline Justified After Q3 Losses?

Xenon Pharmaceuticals recently reported its third quarter and nine-month 2025 financial results, sharing increased net losses compared to the prior year, and participated at the Stifel 2025 Healthcare Conference in New York. The company's focus on neurological therapeutics and ongoing advances in neuroscience research have attracted heightened analyst and investor interest in its development pipeline. We'll explore how growing enthusiasm for Xenon's neuroscience pipeline is shaping the...
NYSE:AVY
NYSE:AVYPackaging

Avery Dennison (AVY): Assessing Valuation After a Steady Month and 8% Share Price Gain

It has been a steady month for Avery Dennison (AVY), despite recent fluctuations in its share price. The stock has shown an 8% gain over the past month. Investors appear to be weighing up its long-term growth prospects amid changing market conditions. See our latest analysis for Avery Dennison. Momentum around Avery Dennison has picked up after a strong 1-month share price return of 8%, even as its year-to-date performance stays in the red and the 12-month total shareholder return remains...